Iambic Therapeutics files for IPO, secures partnerships with AbbVie and Jazz
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
What happened
Iambic Therapeutics filed for a U.S. IPO on September 21, 2026, planning to list on the Nasdaq. The company also announced multi-year collaborations with AbbVie and Jazz Pharmaceuticals. The agreement with AbbVie includes a $40 million upfront payment and potential development and sales-based milestones. Iambic Therapeutics received backing from Nvidia Corporation and Qatar Investment Authority.
Why it matters
The event links AI drug discovery technology, provided by Nvidia Corporation, with major pharmaceutical companies like AbbVie and Jazz Pharmaceuticals. The IPO and partnerships strengthen Iambic Therapeutics' financial position, which increases the value of its collaborations. The company plans to use IPO proceeds to advance three cancer drug candidates through clinical development.
Who's involved
- Jazz PharmaceuticalsPartnered with Iambic Therapeutics to test a drug candidate in HER2-positive breast cancer.
- AbbVieEntered a multi-year research collaboration with Iambic Therapeutics, utilizing its AI platform.
- Qatar Investment AuthorityProvided investment backing to Iambic Therapeutics.
- CitigroupIs underwriting the IPO offering for Iambic Therapeutics.
- NasdaqIs the intended exchange for Iambic Therapeutics' public listing.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Qatar Investment AuthoritySpeculative
Qatar Investment Authority could see an increase in the value of its investment in Iambic Therapeutics.
Keep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
Nothing else this week.
-
AbbVie
pharmaceutical company
-
Qatar Investment Authority
Qatar's sovereign wealth fund founded in 2005